Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith takes Proactive's Stephen Gunnion through the latest findings related to MRX1, the company's lead investigative medicinal product. Developed in 2023, MRX1 targets inflammatory conditions such as chemotherapy-induced peripheral neuropathy and endometriosis, and it is also being studied in heart failure.
Sturgess-Smith explained how leftover blood plasma samples from earlier research were analysed for NT-proBNP, a critical biomarker for heart failure with preserved ejection fraction (HFpEF). He said, "MRX1 was found to significantly reduce the levels of NT-proBNP in the mice versus the control mice." This, according to him, provides strong translational data to justify advancing to human studies.
The results also bolster the company's patent application for MRX1. Ananda is now planning a larger preclinical study to explore additional biomarkers and evaluate MRX1's efficacy. Sturgess-Smith emphasised that the team is beginning to outline steps toward the first human study.
